Richard Franklin, Founder, CEO, and President
Rick is a founder of Pathfinder Cell Therapy and has served as its President and CEO since its inception. He is a director of Raptor Pharmaceuticals, a biotechnology company. Rick is founder and CEO of Tarix Pharmaceuticals.
Joerg Gruber, Founder and Chairman of the Board
Joerg is a founder of Pathfinder Cell Therapy and has served as its Chairman since April 2007. He co-founded Clubb Capital Limited, a London-based corporate finance and venture capital firm with a focus on healthcare, in 1995 and has acted as its Chairman since 1999. Prior to his career in venture capital, Joerg spent 14 years in Banking and Investment Banking at UBS, Goldman Sachs and Lehman Brothers. Joerg is Chairman of Tarix Pharmaceuticals.
Brock Reeve, Director
Brock is a graduate of Yale and the Harvard Business School, and is Executive Director of the Harvard Stem Cell Institute. HSCI is comprised of the schools of Harvard University and all its affiliated hospitals and research institutions. The institute currently has 75 principal faculty and 140 affiliated faculty. Brock’s business career started with the Boston Consulting Group. Prior to Harvard, Brock was COO and Managing Director of Life Science Insights, an IDC company, a consulting and market research firm specializing in information technology in life sciences. Previously, Brock was an Associate Partner in the Pharmaceutical and Life Sciences practice in IBM’s Business Consulting Services group, working with biotech and pharmaceutical clients on issues ranging from R&D portfolios to operations strategies. Brock also has had hands-on operational responsibility in product management and marketing roles in software start-ups as well as additional experience in IT and the healthcare/life science market as the Healthcare Practice Director at Viant Corp. and a Principal at SRI Consulting, where his clients included some of the leading pharmaceutical, biotechnology and medical device companies.
John Brooks III, Director
John is the CEO of the Joslin Diabetes Center. He is the founder of Healthcare Capital Consulting LLC, an advisory services and consulting firm that consults with life science companies, especially early stage start-ups that are seeking strategic advice as well as access to capital to initiate, develop and grow their businesses. John is a founding partner of PrismVentureworks, which is based in Needham, Massachusetts. Prism raised over $1.25B over a twelve year span, of which one-third was targeted in the life sciences sector. John sits on the board of a number of early stage companies, and he is the CEO of Reflectance Medical, a noninvasive tissue perfusion start-up. John was formerly a General Manager at Pfizer/Valleylab in Boulder, Colorado where he developed and executed a successful minimally invasive surgery business and managed an energy based emerging businesses strategy. Prior to that, he was the general manager and president of Pfizer/Strato Medical, a rapidly evolving vascular access medical device business. John has co-founded three paradigm shifting life sciences companies, Songbird Hearing, Locus Pharmaceuticals and Insulet (PODD).
John is a biotechnology advisory board member for Draper Laboratory, the Pittsburgh Life Sciences Greenhouse, the Massachusetts Technology Transfer Council, and the Kansas Heartland Bioventures Fund. He is the Chairman of the Board of Trustees of the Joslin Diabetes Center. John is also a member of M2D2, an early stage medical technology accelerator and a board member of Mass Medic’s Ignite entrepreneurial center as well a member of the CIMIT Technology Advisory Group, the Harvard Medical Cooperative, and he is a Senior Advisor to Johnston Blakely, a life sciences investment banking firm.
John holds an M.S. in Business and a B.B.A. cum laude from the University of Massachusetts at Amherst. He is a Certified Public Accountant and a Certified Financial Planner.
Zen Chu, Director
Zen is the founder of Accelerated Medical Ventures and works as a cofounder, adviser and investor in early stage medical device, consumer healthcare, and connected health ventures. Prior to AMV, he served as the founding Director of Business Development for the Wyss Institute at Harvard Medical School and their internal Accelerator Venture Fund. Earlier, Zen co-founded 3DM Biomaterials along with a group of MIT scientists, serving as the CEO of the venture-backed regenerative medicine company for five years before selling it in 2008. In Silicon Valley, Zen created and directed Hewlett Packard’s HPGarage new technology ventures program. He has also served as an advisor on healthcare innovation to Brigham & Women’s Hospital, Cleveland Clinic, and the Harvard-MIT Division of Health Sciences & Technology (HST). Zen earned a BS in Biomedical/Electrical Engineering from Southern Methodist University and a Masters of Business Administration from Yale University.
John Alam, M.D., Director
John is Head of the Therapeutic Strategic Area for Diseases of Aging for Sanofi-‐Aventis. He is a biopharmaceutical R & D executive who currently advises a number of non-profit organizations and biotechnology companies, including as Senior Medical Advisor to a publicly traded anti-virals company, Inhibitex, Inc. and as an Entrepreneur-in-Residence at a Boston-area venture capital firm. He is also on the executive committee of NEWDIGS, a multi-stake holder public policy-oriented consortium led by the Center for Biomedical Innovation at the Massachussetts Institute of Technology (MIT) to re-design the pharmaceutical development process.
Previously, John played major instrumental roles in the growth and development of two of the top ten US biotechnology companies, Vertex Pharmaceuticals and Biogen (now Biogen Idec). Through to 2008, he was the Executive Vice President, Medicines Development and the Chief Medical Officer for Vertex Pharmaceuticals. In that role, he led regulatory affairs, clinical development, clinical pharmacology, pharmacovigilance, medical affairs, and toxicology. Among other accomplishments at Vertex, he built and led the organization that progressed a major advance in the treatment of hepatitis C, telaprevir (leading hepatitis C protease inhibitor), from pre-clinical development to phase 3 clinical studies. From 1991 to 1997, he led the clinical development from phase 2 to registration and market launch in US and EU of Avonexâ (interferon beta-1a treatment for multiple sclerosis), Biogen’s first commercialized and the leading therapy for multiple sclerosis in the US.
Prior to joining the biopharmaceutical industry, John completed an internal medicine residency at The Brigham and Women’s Hospital and a research fellowship at the Dana-Farber Cancer Institute. He holds an M.D. from Northwestern University Medical School and an S.B. in chemical engineering from MIT.
John serves on the Board of Trustees of the non-profit Accelerated Cure Project for Multiple Sclerosis, the Board of Overseers of WGBH (television and radio stations, and US public television content provider), and the Board of Trustees of The International School of Boston (French-English pre-K through 12th grade school).